Friday, June 24, 2022

+91 9930709000

Zaltrap

Zaltrap

Zaltrap (ziv-aflibercept) is a recombinant fusion protein indicated for the treatment of metastatic colorectal cancer (mCRC). It was developed by Sanofi-Aventis in collaboration with Regeneron Pharmaceuticals. Zaltrap (ziv-aflibercept) is a recombinant fusion protein indicated for the treatment of metastatic colorectal cancer (mCRC). It was developed by Sanofi-Aventis in collaboration with Regeneron Pharmaceuticals.

In August 2012, Zaltrap was approved by the US Food and Drug Administration (FDA) for the treatment of patients suffering from metastatic colorectal cancer following treatment with oxaliplatin. Colorectal cancer, also known as colon cancer, originates in the large intestine or the rectum. The symptoms of the disease include rectal bleeding and anaemia, which also may be associated with weight loss and changes in bowel habits. It is the leading cause of cancer-related deaths in the US.

According to the American Cancer Society’s estimates, in 2012 more than 143,000 new cases were diagnosed, of which more than 51,000 are expected to die. More than 60% of those diagnosed have advanced or metastatic disease.

More than 1.2 million people were diagnosed with the disease worldwide in 2008, of which over 60,000 died in the same year.

Zaltrap’s mechanism of action

Zaltrap contains is a recombinant fusion protein, which is produced by using recombinant DNA technology. The drug binds endogenous ligands and inhibits the binding and activation of the cognate receptors. The drug decreases neovascularisation and thereby reduces the vascular permeability. It is available in injection form for intravenous infusion.

Clinical trials on ziv-aflibercept / Zaltrap

Sanofi-Aventis in collaboration with Regeneron conducted phase I clinical trials on Zaltrap between March 2007 and January 2011. It was an open label, dose-escalation, and parallel assignment. The primary outcome measure of the study was finding out the dose-limiting toxicity (DLT). The secondary outcome measures included finding the drug’s safety, pharmacokinetic values, and objective response rate.

Sanofi-Aventis conducted a phase II clinical trial on Zaltrap between February 2009 and January 2012. It was an open label, randomised, and multinational clinical study. The study enrolled 268 patients with metastatic colorectal cancer. The primary outcome measure of the study was finding the progression free survival rate (PFS). The secondary outcome measures included finding the overall response rate, progression-free survival, and overall survival.

LEAVE A REPLY

Please enter your comment!
Please enter your name here